These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35758639)

  • 41. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel M(1) allosteric ligands: a patent review.
    Kuduk SD; Beshore DC
    Expert Opin Ther Pat; 2012 Dec; 22(12):1385-98. PubMed ID: 23092292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
    Verma S; Kumar A; Tripathi T; Kumar A
    J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Electron Donor-Acceptor Properties of Different Muscarinic Ligands: On the Road to Control Schizophrenia.
    Goode-Romero G; Dominguez L; Martínez A
    J Chem Inf Model; 2021 Oct; 61(10):5117-5124. PubMed ID: 34555904
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.
    McArthur RA; Gray J; Schreiber R
    Curr Opin Investig Drugs; 2010 Jul; 11(7):740-60. PubMed ID: 20571970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

  • 49. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
    Scarpa M; Hesse S; Bradley SJ
    Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.
    Langmead CJ; Austin NE; Branch CL; Brown JT; Buchanan KA; Davies CH; Forbes IT; Fry VA; Hagan JJ; Herdon HJ; Jones GA; Jeggo R; Kew JN; Mazzali A; Melarange R; Patel N; Pardoe J; Randall AD; Roberts C; Roopun A; Starr KR; Teriakidis A; Wood MD; Whittington M; Wu Z; Watson J
    Br J Pharmacol; 2008 Jul; 154(5):1104-15. PubMed ID: 18454168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
    Christopoulos A; Parsons AM; El-Fakahany EE
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia.
    Dean B; Scarr E
    Psychiatry Res; 2020 Jun; 288():112989. PubMed ID: 32315882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Muscarinic agonists for the treatment of cognition in schizophrenia.
    Sellin AK; Shad M; Tamminga C
    CNS Spectr; 2008 Nov; 13(11):985-96. PubMed ID: 19037177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine.
    Li Z; Snigdha S; Roseman AS; Dai J; Meltzer HY
    Eur J Pharmacol; 2008 Oct; 596(1-3):89-97. PubMed ID: 18771666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Schizophrenia: moving beyond monoamine antagonists.
    Conn PJ; Tamminga C; Schoepp DD; Lindsley C
    Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.
    Friedman JI
    Psychopharmacology (Berl); 2004 Jun; 174(1):45-53. PubMed ID: 15205878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bitopic Binding Mode of an M
    Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
    Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery and Development of Muscarinic Acetylcholine M
    Takai K; Enomoto T
    Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Muscarinic Acetylcholine Receptor M
    Bender AM; Garrison AT; Lindsley CW
    ACS Chem Neurosci; 2019 Mar; 10(3):1025-1034. PubMed ID: 30280567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.